Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies
Express News | Ocugen Inc - to Pursue Accelerated Marketing Authorization Application for Ocu410St
Express News | Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies Including Stargardt Disease
Ocugen, Inc. Reports Positive Preliminary Data From OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration
Ocugen Announces Preliminary Data For OCU410l; Findings Included No Drug-related Serious Adverse Events, Reduced Lesion Growth, Preservation Of Retinal Tissue, Positive Effect On The Functional Visual Measure Of Low Luminance Visual Acuity
